BioLife Solutions Adopts New Brand Identity

BioLife today announced the launch of its new corporate brand identity, redesigned logo, and website. The new brand identity was created to better reflect BioLife’s expanded portfolio of bioproduction tools and services. Todd Berard, Chief Marketing Officer, remarked, “We pursued a refreshed design that appropriately positions BioLife as the premier supplier of cell and gene…

Read More

Journal Articles Citing CryoStor CS10® Recently Added to BioLife Solutions’ Evidence Library

Multiple Uses for CryoStor in Cell Manufacturing Journal articles recently added to BioLife Solutions’ Evidence Library illustrate several stages during the cell manufacturing process for which CryoStor CS10® cryopreservation solution is applicable. The three articles that follow include several different cell types cryopreserved in CryoStor CS10. An expanded list of cell types biopreserved in BioLife…

Read More

SAVSU Technologies Announces Major evo.is® Cold Chain SaaS Update and New evo® Extreme Product Line for Shipping Cell Therapies

evo System Adopted by Leading Specialty Logistics Service Providers and Cell Therapy Manufacturers as Best Practice On May 2, 2018, our Joint Venture partner,  SAVSU Technologies, the leading developer of smart precision shipping containers and cloud-based cold chain management SaaS solutions, announced two major upgrades to its industry best evo system; including enhanced software and shipping…

Read More

CGTI Alireza Article Blog Post

Biopreservation Best Practices: A Cornerstone in the Supply Chain of Cell-based Therapies – MSC Model Case Study

Mesenchymal stromal cells (MSCs) are prime candidates for regenerative medicine and therapeutic applications due to both their potent immuno- modulatory function and a unique ability to proliferate and differentiate into a variety of cell lineages. However, the stresses incurred during biopreservation/stability intervals (non-frozen and cryopreserved), including transit to and from the clinic can render MSCs ineffective and potentially unsafe.…

Read More

BioLife Solutions Announces Preliminary 2017 Revenue Increase of 34% to $11 Million

Q4 2017 Preliminary Revenue Reaches Record $3.1 Million, up 39% over Q4 2016 On January 4, 2018 BioLife Solutions Inc. (NASDAQ: BLFS) (“BioLife”), the leading developer, manufacturer and marketer of proprietary clinical-grade cell and tissue hypothermic storage and cryopreservation freeze media, announced preliminary Q4 and full year 2017 revenue and provided additional operational updates and financial guidance for 2018.…

Read More


Iovance Blog Post

BioLife Solutions Executes Supply Agreement with Iovance Biotherapeutics

On December 13, 2017 BioLife Solutions Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade biopreservation media (“BioLife” or the “Company”), announced that it has executed an agreement to supply its CryoStor® cell freeze media and HypoThermosol® cell storage and shipping media to Iovance Biotherapeutics, Inc. (“Iovance”) (NASDAQ: IOVA). Iovance is…

Read More

TissueGene Blog Post

Kolon Life Science Launches Osteoarthritis Drug Invossa in Korea

Kolon Life Science Launches Osteoarthritis Drug Invossa in Korea A huge congratulations to BioLife customer TissueGene / Kolon Life Science on their first patient use of CryoStor – powered Invossa, a novel cell-mediated therapy for degenerative arthritis. Invossa is the world’s first gene therapy for treating osteoarthritis of the knee, in which the cartilage that cushions…

Read More


BioLife Solutions Executes Supply Agreement with Celyad

BioLife Solutions Executes Supply Agreement with Celyad for CryoStor® Use in Natural Killer Receptor based T-Cell (NKR-T) Platform Targeting Solid Tumors and Blood Cancers Proprietary Clinical Grade Cell Freeze Media Enables Long-Term Storage and Distribution of Engineered Cell-Based Therapies BioLife is pleased to announce that it has executed a long term supply agreement with NASDAQ-listed Celyad,…

Read More